Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients

European Psychiatry

Volumn 12, Issue 6, 1997, Pages 294-299

  Muller N ^a   Dobmeier, P ^a   Empl, M ^a   Riedel, M ^a   Schwarz, M ^a   Ackenheil, M ^a  

^a Psychiatric Hospital   (Germany)

Author keywords

Cerebrospinal fluid; Cytokines; Interleukin 6; Schizophrenia; sIL 6R

Indexed keywords

CYTOKINE; INTERLEUKIN 6 RECEPTOR;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOREGULATION; MALE; MENTAL DISEASE; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SERUM;

EID: 0030812780     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)84789-X     Document Type: Article

References (39)

1. Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. Das AMDP System. Berlin: Springer, 1979
2. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 1994;179:53-6
3. Bauer K, Kornhuber J. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur Arch Psychiatr Neurol Sci 1987;236:257-9
4. Bobon D, Baumann U, Angst J, Helmchen H, Hippius H, eds. AMDP System in Pharmacopsychiatry. Basel: Karger, 1983
5. De Vries HE, Blom-Rosemalen MCM, van Oosten M, de Boer AG, van Berkel TJC, Breimer DD et al. The influence of cytokines to the integrity of the blood brain barrier in vitro. J Neuroimmunol 1996;64:37-43
6. Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther 1992;261:964-9
7. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J Immunol 1989;19:689-94
8. Galinowski A, Barbouche R, Truffinet P, Louzir H, Poirier MF, Bouvet O et al. Natural autoantibodies in schizophrenia. Acta Psychiatr Scand 1992;85:240-2
9. Ganguli R, Rabin BS, Kelly RH. Multiple autoantibodies and autoimmune disease in schizophrenic patients: evidence for an autoimmune pathogenesis. In: Hadden JW, Masek K, Nistico G, eds. Interactions Among Central Nervous System, Neuroendocrine and Immune Systems. Rome-Milan: Pythagora Press, 1989;364-85
10. Ganguli R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994;51:1-10
11. Gebhardt R, Pietzcker A, Strauss A, Stoeckl M, Langer C, Freudenthal K. Scale building in the AMDP system. Arch Psychiatr Neurol Sci 1983;233:223-45
12. Großkopf A, Müller N, Malo A, Wank R. HLA-DR and DQ alleles in schizophrenics and manic depressive disorders: potential role for the narcolepsy and multiple sclerosis associated allele DQB1*0602 in schizophrenia subtypes. Schizophr Res 1996; (in press)
13. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. Interleukin-6 improves the survival of mesencephalic catochelaminergic and septal cholinergic neurons from patnatal, two-week-old rats in cultures. Neuroscience 1991;40:445-52
14. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995;15: 237-42
15. Kirch DG, Kaufmann CA, Papadopoulos NM, Martin B, Weinberger DR. Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 1985;20:1039-46
16. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated levels of interleukin-2 in neuroleptic-free schizophrenics. Am J Psychiatry 1993;150:1408-10
17. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;49: 2021-7
18. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38
19. Maes M, Meltzer HY, Scharpé S, Bosmans E, Suy E, De Meester I et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993a;49:11-27
20. Maes M, Scharpé S, Meltzer HY, Bosmans E, Suy E, Calabrese J et al. Relationships between lower plasma L-Tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993b;49:151-65
21. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenics: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994;89:346-51
22. Maes M, Bosmans E, Meltzer HY. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatr Clin Neurosci 1995a;245:172-8
23. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995b;29:141-52
24. McAllister CG, van Kammen DP, Rehn TJ, Miller AN, Gurklis J, Kelley ME et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;152:1291-7
25. Müller N. The role of the cytokine-network in the CNS, and psychiatric disorders. Nervenarzt 1997;68:11-20
26. Müller N, Ackenheil M. The immune system and schizophrenia. In: Leonard B, Miller K, eds. Stress, Immune System and Psychiatry. Chichester, New York: Wiley & Sons, 1995a;137-64
27. Müller N, Ackenheil M. Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophr Res 1995b;14:223-8
28. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R. Cellular immunity in schizophrenic patients before and during neuroleptic therapy. Psychiatry Res 1991;37:147-60
29. Müller N, Ackenheil M, Hofschuster E, Mempel W, Eckstein R. Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:713-30
30. Müller N, Empl M, Putz A, Schwarz M, Ackenheil M. Immunological effects of treatment in schizophrenia. Adv Biol Psychiatry 1997;18:78-84
31. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K et al. The essential role of B-cell stimulating factor 2 (BSF-2/Il-6) for the terminal differentiation of the B-cells. J Exp Med 1988;167:332-44
32. Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci Behav Rev 1991;15:185-215
33. Saija A, Princi P, Lanza M, Scalese M, Aramnejad E, De Sarro A. Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci 1995;56:775-84
34. Sawada M, Suzumura A, Marunouchi T. TNF-α induces IL-6 production by astrocytes, but not by microglia. Brain Res 1992;583:296-9
35. Schöbitz B, Pezeshki G, Pohl T, Hermann U, Heinrich PC, Holsboer F et al. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 1995;9:659-64
36. Seiler W, Muller H, Hiemke C. Diurnal variations of plasma interleukin-6 in man: methodological implications of continuous use of indwelling cannulae. Ann NY Acad Sci 1995; 762:468-70
37. Smith RS. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 1992;39:248-57
38. Song C, Leonard BE. An acute phase protein response in the olfactory bulbectomised rat: effect of sertraline treatment. Med Sci Res 1994;22:313-4
39. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994; 643:40-9